<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00886626</url>
  </required_header>
  <id_info>
    <org_study_id>0902M59181</org_study_id>
    <nct_id>NCT00886626</nct_id>
  </id_info>
  <brief_title>GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children</brief_title>
  <official_title>GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children: A Randomized, Controlled, Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of severely obese children is on the rise. Behavioral therapies for weight
      loss are successful in some, but others need more aggressive approaches such as drug therapy.
      In addition, up to 25% of severely obese children have impaired glucose tolerance (IGT),
      which places them at significantly elevated risk of developing type 2 diabetes mellitus and
      cardiovascular disease. Although various drug therapies for weight loss and IGT have been
      explored in adults, few have been evaluated in children.

      Recently, a new drug class has emerged that targets deficiencies of GLP-1. One of the main
      glycemic mechanisms of action of the GLP-1 agonists such as exenatide is to enhance glucose
      disposal in the postprandial setting and improve glucose tolerance. In addition, exenatide
      can induce weight loss by decreasing appetite and slowing gastric motility.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, open-label, controlled, crossover clinical trial in 12 patients.
      All patients will receive exenatide and undergo the control phase. Following baseline
      testing, participants will be randomly assigned to treatment order: therapy (exenatide) or
      control (lifestyle modification). Half (n = 6) will receive exenatide first (3-months) then
      cross over to control (no drug therapy for 3-months). Half (n = 6) will be assigned to
      control first (3-months) then cross over to exenatide (3-months). All efforts will be made to
      stratify randomization based on gender of the participants. Treatment and control conditions
      will be three months each. Because of the route of administration of exenatide (subcutaneous
      injection), placebo will not be utilized for the control phase of the study.

      Participants in this study will engage in background intensive lifestyle modification offered
      by the University of Minnesota Pediatric Weight Management Clinic for the entire study, even
      during the active drug treatment phase. Intensive lifestyle modification will be purely
      clinical in nature in which children and their families receive continuing counseling from a
      team of trained professionals including physicians, dieticians, and psychologists to reduce
      weight by making healthier eating choices and increasing physical activity.

      The screening visit will take place in the Pediatric Weight Management Clinic and will
      include a complete medical history and physical examination. Screening will include review of
      medical records for previous clinical and laboratory data (including clinically-ordered
      glucose tolerance test results). All research testing will take place in the University of
      Minnesota General Clinical Research Center (GCRC). Subjects will undergo testing at the
      following intervals: baseline, immediately after the first 3-month phase (whether exenatide
      or control), and immediately after the second 3- month phase (whether exenatide or control).
      The following measures will be collected after the subject has been fasting for at least
      twelve hours:

        -  Height, weight, body mass index, waist and hip circumference

        -  Fat and lean mass (dual energy x-ray absorptiometry: DXA)

        -  Tanner stage determination (performed during screening physical exam or may be obtained
           from medical chart)

        -  Fasting lipid profile (total-, LDL-, and HDL-cholesterol, triglycerides)

        -  Systolic and diastolic blood pressure

        -  Oral glucose tolerance test (glucose and insulin measured every 30 minutes for 2 hours)

        -  Endothelial function (digital reactive hyperemia: EndoPAT 2000, Itamar Medical) - in
           addition to the baseline measure, endothelial function testing will occur at hours one
           and two of the oral glucose tolerance test

        -  Frozen plasma for storage - in addition to the baseline blood draw, blood for
           endothelial biomarkers will be obtained at hours one and two of the oral glucose
           tolerance test

        -  Arterial stiffness (pulse wave velocity; augmentation index: Sphygmocor, AtCor Medical)

        -  Frozen plasma for pharmacokinetic determination of exenatide in children
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Body Mass Index (BMI)</measure>
    <time_frame>3-month</time_frame>
    <description>Change in body mass index (BMI) over three months</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Obesity, Morbid</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Exenatide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control - no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>Exenatide, subcutaneous injection, 10 mcg, twice per day</description>
    <arm_group_label>Exenatide</arm_group_label>
    <other_name>Byetta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 8-19 years old

          -  Subject able to give assent, and parent/guardian capable of giving consent on behalf
             of the child

          -  Body mass index (BMI) ≥ 99th percentile (based on gender and age)

        Exclusion Criteria:

          -  Type 1 or 2 diabetes mellitus

          -  Initiation of a new drug therapy within the past 30 days prior to the screening visit

          -  BMI ≥ 55

          -  History of weight loss surgery

          -  Obesity from a genetic cause (e.g., Prader-Willi)

          -  Central nervous system injury or severe neurological impairment

          -  Known systolic or diastolic dysfunction or heart failure

          -  Females who are currently pregnant or planning to become pregnant

          -  Liver enzymes &gt; 2.5 times upper limit of normal

          -  Severe renal impairment (defined as creatinine clearance &lt;30 mL/min)

          -  Gastrointestinal disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>19 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aaron S. Kelly, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Minnesota - Clinical and Translational Science Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 22, 2009</study_first_submitted>
  <study_first_submitted_qc>April 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 23, 2009</study_first_posted>
  <results_first_submitted>April 25, 2012</results_first_submitted>
  <results_first_submitted_qc>July 9, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 17, 2012</results_first_posted>
  <last_update_submitted>October 22, 2012</last_update_submitted>
  <last_update_submitted_qc>October 22, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Obesity</keyword>
  <keyword>Impaired Glucose Tolerance</keyword>
  <keyword>Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment occurred from October 2009 - August 2010; participants were recruited from medical clinics in the Minneapolis-St. Paul area.</recruitment_details>
      <pre_assignment_details>29 patients qualified for the study and were approached about participation. 12 agreed to participate.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Exenatide Then Control</title>
          <description>Exenatide 5 mcg for 1-month then uptitration to 10-mcg for remaining 2-months followed by control for 3-months</description>
        </group>
        <group group_id="P2">
          <title>Control Then Exenatide</title>
          <description>No medication control for 3-months then exenatide 5 mcg for 1-month uptitrated to 10 mcg for following 2-months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1 (90 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 2 (90 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>All enrolled participants</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Body Mass Index (BMI)</title>
        <description>Change in body mass index (BMI) over three months</description>
        <time_frame>3-month</time_frame>
        <population>Data from all participants who completed the trial were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Exenatide</title>
            <description>Exenatide 5 mcg for 1-month then up-titration to 10-mcg for remaining 2-months. Participants came from period 1 and period 2.</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>No medication control for 3-months. Participants came from period 1 and period 2.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Body Mass Index (BMI)</title>
          <description>Change in body mass index (BMI) over three months</description>
          <population>Data from all participants who completed the trial were analyzed.</population>
          <units>change in kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.2"/>
                    <measurement group_id="O2" value="0.84" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6-month</time_frame>
      <desc>Adverse Events were evaluated over length of study (6 months; 180 days)</desc>
      <group_list>
        <group group_id="E1">
          <title>Exenatide</title>
          <description>Exenatide 5 mcg for 1-month then uptitration to 10-mcg for remaining 2-months.</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>No medication control for 3-months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample size; un-blinded; crossover study design</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Aaron S. Kelly, Ph.D.</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-3492</phone>
      <email>kelly105@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

